Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 314
Selected: 0
NCT IDTitle
NCT02605993Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT00739505Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
NCT02306720Registry of Patients With Hypophosphatasia
NCT01180790Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
NCT06208488A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
NCT02496689Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
NCT00952484Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
NCT04469465Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
NCT05314231Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
NCT06312644Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT03131219Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT01221181Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
NCT03369236A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
NCT04920370Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
NCT00844428Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
NCT04201262An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
NCT01755429To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
NCT01633489Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01410916Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
NCT04933682Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
NCT03397888The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist
NCT05303324Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
NCT04610580Bioavailability Study of 2 Oral Formulations of ALXN1840
NCT04526210Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
NCT03766347Pediatric NMOSD Observational Study
NCT03748823Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
NCT02145182Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
NCT04609696Study of the Metabolism of Danicopan in Healthy Adults
NCT04256148ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
NCT05319899A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT01335165Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01095887Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
NCT01765855An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects
NCT04195763Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT02090179Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging
NCT01583218Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
NCT04422431Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
NCT01892345A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
NCT02245412A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
NCT00122330Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
NCT01765868A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers
NCT02372513National Lysosomal Acid Lipase Deficiency Study
NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
NCT05556096Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT01994382Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
NCT05982938Danicopan Early Access Program
NCT05047458A Study of Single-dose ALXN2050 in Healthy Adults
NCT02376751An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency
NCT00122304Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab